JNJ logo Johnson & Johnson +
Johnson & Johnson
+

Johnson & Johnson (JNJ) Business News

Track Johnson & Johnson in real time with a live news feed covering Johnson & Johnson stock news, official press releases, company announcements, and an archive of historical Johnson & Johnson news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
7:45 AM | Wednesday | Jul 8, 2026 Business Wire

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

News Thumbnail
12:35 PM | Friday | Jun 26, 2026 PRNewsWire

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

News Thumbnail
5:00 AM | Thursday | Jun 25, 2026 Business Wire

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

News Thumbnail
6:00 AM | Monday | Jun 15, 2026 Business Wire

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

News Thumbnail
7:45 AM | Thursday | Jun 11, 2026 Business Wire

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

News Thumbnail
2:03 AM | Thursday | Jun 11, 2026 PRNewsWire

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

News Thumbnail
11:22 AM | Wednesday | Jun 10, 2026 Business Wire

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

News Thumbnail
8:00 AM | Monday | Jun 8, 2026 Business Wire

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

News Thumbnail
6:34 AM | Thursday | Jun 4, 2026 PRNewsWire

CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus

News Thumbnail
12:04 AM | Wednesday | Jun 3, 2026 PRNewsWire

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

News Thumbnail

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Business Wire

7:45 AM | Wednesday | Jul 8, 2026

news photo
Loading...

IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform.

Read full article redirect
7:45 AM | Wednesday | Jul 8, 2026

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform.

Read full article arrow
News Thumbnail
12:35 PM | Friday | Jun 26, 2026

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

PRNewsWire

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+ a , anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including those early in their disease, participants with lower symptom burden and those who experienced  common infections To address an important evidence gap, the PETUNIAc study design will be presented – demonstrating the innovative way pregnancy outcomes data will be collected following treatment with IMAAVY IMAAVY, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with generalized myasthenia gravis (gMG) GENEVA, June 26, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of... Read more

Read full article arrow
News Thumbnail
5:00 AM | Thursday | Jun 25, 2026

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson advances cardiac ablation technology in Europe with availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform.

Read full article arrow
News Thumbnail
6:00 AM | Monday | Jun 15, 2026

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Business Wire

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare's leading, most comprehensive innovation powerhouse, today announced an investment of more than $1 billion in Jacksonville, Florida to strengthen its Vision operations by scaling U.S.-based manufacturing, packaging and distribution capabilities.
The investment includes construction of a new, state-of-the-art distribution facility, alongside advanced manufacturing and packaging technologies to exp.

Read full article arrow
News Thumbnail
7:45 AM | Thursday | Jun 11, 2026

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Business Wire

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs). TECNIS PureSee IOL is an extended depth of focus (EDOF) lens designed to support visual clarity and quality for patients undergoing cataract surgery.
3 Benefits of TECNIS PureSee IOL: Range of vision: Excellent distance and intermediate vision with some near vision3* Low level of bothersome visual symptoms: 97% of p.

Read full article arrow
News Thumbnail
2:03 AM | Thursday | Jun 11, 2026

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

PRNewsWire

Patients in the IMAAVY 30 mg/kg treatment group a achieved statistically significant durable hemoglobin response b , with mean hemoglobin improvement of at least 1 g/dL as early as Week 1 c   More patients treated with IMAAVY experienced improvement in fatigue d and corticosteroid dose reductions e IMAAVY is designed to target pathogenic immunoglobulin G (IgG) autoantibodies in warm autoimmune hemolytic anemia while preserving immune function Pivotal results will be presented at EHA 2026 STOCKHOLM, June 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY® (nipocalimab-aahu) produced a statistically significant durable hemoglobin (Hgb) responseb with rapid onset of effect in patients with warm autoimmune hemolytic anemia (wAIHA)e in the 30 mg/kg treatment group,a compared with those who received placebo. The randomized, placebo-controlled trial demonstrated approximately three... Read more

Read full article arrow
News Thumbnail
11:22 AM | Wednesday | Jun 10, 2026

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Business Wire

LOS ANGELES--(BUSINESS WIRE)-- #JohnsonJohnson--A Los Angeles jury has awarded $32 million to the family of a California woman who died from pleural mesothelioma after years of exposure to an asbestos-contaminated talc product, finding Johnson & Johnson (NYSE: JNJ) and its subsidiaries liable for her illness. Maria Lozano died from mesothelioma in 2024. Her children, John Lozano, Araceli Lenard-Lozano and Jeanette Lozano, continued the lawsuit after her death. View the verdict form and photos here. During th.

Read full article arrow
News Thumbnail
8:00 AM | Monday | Jun 8, 2026

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Business Wire

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ DAC platform for KRAS-driven tumors bolsters Johnson & Johnson's oncology pipeline and ambition to develop targeted medicines for the most prevalent and hard-to-treat solid tumors with high un.

Read full article arrow
News Thumbnail
6:34 AM | Thursday | Jun 4, 2026

CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus

PRNewsWire

Financing led by Piper Sandler Merchant Banking, with participation from new investors Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson's corporate venture capital arm, and Medtronic Participation by existing investors, including Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds Proceeds will support the conclusion of the STRIDE pivotal trial, continued operational scale-up, advancement of regulatory work toward a future Premarket Approval (PMA) submission to the FDA, and preparations for US commercialization Board strengthened with addition of Kevin Conroy as Lead Independent Director, Christopher Geyen as Chair of the Audit Committee, and Tom Schnettler representing Series C investors BOSTON, June 4, 2026 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel, minimally invasive treatments for neurological diseases, today announced it has successfully completed the initial closing... Read more

Read full article arrow
News Thumbnail
12:04 AM | Wednesday | Jun 3, 2026

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

PRNewsWire

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with this disease while preserving immune function Results demonstrated significant reduction of systemic lupus erythematosus disease activity which continued beyond the 24-week primary endpoint, and were sustained through Week 52 in the nipocalimab 15 mg/kg groupa The ongoing Phase 3 study of nipocalimab is currently recruiting people living with systemic lupus erythematosus – a debilitating autoantibody-driven disease which can lead to systemic organ damage LONDON, June 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index 4 (SRI-4)b and continued to... Read more

Read full article arrow
News Thumbnail